脂肪移植在乳房再造中的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项研究,评估乳房切除术后自体脂肪移植的并发症与体积保持率。非富集移植6项研究报告3-12个月体积保持率26.0%-74.8%,合并平均47%(95%CI 31.5-62.5;I2=99%)。脂肪移植与脂肪坏死风险数值升高但无统计学意义(RR 2.37;95%CI 0.80-7.01),患者报告结局持续支持脂肪移植。
要点
- 非富集脂肪移植合并体积保持率47%(95%CI 31.5-62.5),排除皮瓣辅助和水射流研究后为35.1%。
- 脂肪坏死风险数值升高但无统计学意义(RR 2.37;95%CI 0.80-7.01),各并发症类别无显著差异。
- 患者报告结局(主要为Breast-Related Quality of life Questionnaire)持续支持脂肪移植。
核心结论
- 脂肪移植是乳房切除术后乳房再造的安全辅助手段,体积保持中等且不增加术后发病率。
- 患者满意度随脂肪移植持续改善,需标准化体积评估和技术特异性分层以优化结局。
研究设计与样本
- 遵循PRISMA的系统综述与荟萃分析(PROSPERO CRD420251132758),检索Medline、Embase、CENTRAL和Scopus(2010-2025年)。
- 纳入13项比较研究,评估脂肪移植后并发症或体积保持率,采用随机效应模型以I2和τ2评估异质性。
主要发现
- 6项非富集研究报告3-12个月体积保持率26.0%-74.8%,合并平均47%(95%CI 31.5-62.5;I2=99%)。
- 排除皮瓣辅助和水射流研究后合并保持率降至35.1%(95%CI 25.9-44.3)。
- 随访时间未显著导致中等保持率(p=0.97)。
- 富集移植技术显示更高保持率(78-89%)但异质性过大无法合并。
- 7项研究参与并发症分析,脂肪坏死风险比RR 2.37(95%CI 0.80-7.01),无统计学意义;各并发症类别无显著差异,放疗队列并发症率相当。
关键数值与推荐
- 非富集脂肪移植合并体积保持率47%(95%CI 31.5-62.5;I2=99%)。
- 排除皮瓣辅助和水射流研究后合并保持率35.1%(95%CI 25.9-44.3)。
- 脂肪坏死风险比RR 2.37(95%CI 0.80-7.01)。
- 富集移植技术保持率78-89%(异质性过大未合并)。
- 随访时间与中等保持率无显著关联(p=0.97)。
临床怎么用
- 脂肪移植可作为乳房切除术后乳房再造的安全辅助手段,用于改善轮廓和组织质量。
- 应告知患者脂肪坏死风险可能数值升高但无统计学意义,患者满意度可能改善。
- 需采用标准化体积评估和技术特异性分层以优化 outcomes。
局限性
- 非富集研究合并体积保持率异质性极高(I2=99%)。
- 富集移植技术研究异质性过大无法合并分析。
- 脂肪坏死风险比未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous fat grafting (AFG) is increasingly used in postmastectomy breast reconstruction to enhance contour, improve tissue quality, and address radiation-induced fibrosis. However, uncertainty remains regarding long-term volume retention, complication risks, and patient-reported outcomes, particularly in oncologic populations. METHODS: This Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis (PROSPERO CRD420251132758) searched Medline, Embase, CENTRAL, and Scopus (2010-2025) for comparative studies evaluating complications or volume retention after AFG. Random-effects modeling assessed heterogeneity using I2 and τ2. Sensitivity analyses excluded flap-augmented and water jet-assisted techniques. Enriched graft methods were synthesized narratively. RESULTS: Thirteen studies were included. Six nonenriched studies reported volume retention ranging from 26.0% to 74.8% at 3 to 12 months. The pooled mean retention was 47% [95% confidence interval (95% CI), 31.5-62.5; I2=99%]. Excluding flap-augmented and water jet studies yielded a lower pooled retention rate of 35.1% (95% CI, 25.9-44.3). Follow-up time did not significantly lead to moderate retention (p=0.97). Enriched grafting techniques demonstrated higher retention (78-89%) but were too heterogeneous for pooling. Seven studies contributed to complication analysis. AFG was associated with a numerically higher rate of fat necrosis [risk ratio (RR), 2.37; 95% CI, 0.80-7.01], although this did not reach statistical significance. No significant differences were observed in any complication category. Complication rates were comparable in irradiated cohorts. Patient-reported outcomes (primarily the Breast-Related Quality of life Questionnaire) consistently favored AFG. CONCLUSION: AFG is a safe adjunct in postmastectomy breast reconstruction, demonstrating moderate volume retention without increased postoperative morbidity. Patient satisfaction consistently improves with AFG. Standardized volumetric assessment and technique specific stratification are needed to optimize outcomes.
引用
- Ahn J, Ahn J, Shiatis A, et al. Efficacy and safety of fat grafting in breast reconstruction: A systematic review and meta-analyses of outcomes following mastectomy. J Plast Reconstr Aesthet Surg. 2026. PMID: 42202560. doi:10.1016/j.bjps.2026.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。